

Crispr Therapeutics AG (CRSP)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001674416

Crispr Therapeutics AG

CRSP; healthcare

Grade	A		strongest fifth of 371 graded peers percentile 5.7; sampling error 2.5 points; lower is stronger
Rank	22 of 371		
Profitability	B/C		percentile 39.8
Solvency	A		percentile 13.6
Growth and financing	B/C		percentile 39.8
Reliability	0.91 AUC		filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year		Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets		total assets \$2.3B
Standard universe	inside		revenue above \$1M and assets above \$10M
Warnings	none active		not computable: fortress balance sheet
Inputs computable	7 of 14		
Graded from	filings received through Feb 12, 2026		239 days before the rescans; latest periodic filing 10-Q received Aug 3, 2026
Last close	\$50.41		2026-10-08; market equity \$4.9B
Price used in grade	None		




A, the bull

strongest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



The chart shows a significant decline in share price over the period. The first 'A' is at a peak near \$45, followed by a sharp drop. The second 'A' is at a local peak around \$35. The price ends at \$50.44.

Rescans on file: A from Feb 21, 2022, A from Aug 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

[illegible]

Business, in the company's words

opening of Item 1 of the 10-K received Feb 12, 2026

Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a

CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 39.8						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(10.5%)	(6.6%)	39.8	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 13.6						
Twelve-month failure probability		0.03%	0.07%	15.8	248	2026-06-30
Altman Z double-prime		6.42	(0.31)	15.2	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		13.32x	2.96x	9.7	839	2025-12-31
Growth and financing, sleeve percentile 39.8						
Revenue growth, three-year compound		43.1%	10.0%	15.2	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000 pretax income must exceed the validity floor and imply a 0%-100% tax rate
Reinvestment rate		not computable	37.1%			
Asset growth, three years		0.3%	2.1%	50.9	704	2025-12-31
Net share issuance, one year		11.9%	2.5%	53.2	634	2026-02-10

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
17	Ideaya Biosciences, Inc. (IDYA)	4.3	A	
18	Vericel Corp. (VCEL)	4.6	A	
19	Tarsus Pharmaceuticals, Inc. (TARS)	4.9	A	fortress
				balance sheet
20	Biomarin Pharmaceutical Inc. (BMRN)	5.1	A	
21	Neurocrine Biosciences Inc. (NBIX)	5.4	A	
22	Crispr Therapeutics AG (CRSP) <	5.7	A	
23	SBC Medical Group Holdings Inc. (SBC)	6.1	A	fortress
				balance sheet
24	SBC Medical Group Holdings Inc. (SBCWW)	6.1	A	fortress
				balance sheet
25	United Therapeutics Corp. (UTHR)	6.5	A	
26	AtriCure, Inc. (ATRC)	6.8	A	
27	Intuitive Surgical Inc. (ISRG)	7.0	A	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(12.1%)	8.0%	37
Distance from 52-week high	(34.3%)	(31.4%)	45
EBIT to enterprise value	(12.8%)	(1.5%)	29
Free cash flow yield	(7.1%)	(1.0%)	37
Book value to price	0.36	0.28	58
Sales to price	0.00	0.31	3
Composite equity issuance, five years	24.8%	20.3%	53
Relative strength against the sector, log excess return	(0.34)	(0.14)	37

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$291.3M
Operating cash flow, four quarters	-\$369.6M
Months of runway	9.5

Days since last periodic filing

67 (10-Q received Aug 3, 2026)

Median daily dollar volume, 63 sessions

\$76.0M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$581.6M	2025-12-31	2026-02-12	10-K	0001193125-26-048957
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$345.0M	2025-12-31	2026-02-12	10-K	0001193125-26-048957
3	assets	us-gaap:Assets	\$2.3B	2025-12-31	2026-02-12	10-K	0001193125-26-048957
4	assets	us-gaap:Assets	\$2.2B	2024-12-31	2026-02-12	10-K	0001193125-26-048957
5	current assets	us-gaap:AssetsCurrent	\$2.0B	2025-12-31	2026-02-12	10-K	0001193125-26-048957
6	current liabilities	us-gaap:LiabilitiesCurrent	\$149.1M	2025-12-31	2026-02-12	10-K	0001193125-26-048957
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.9B	2025-12-31	2026-02-12	10-K	0001193125-26-048957
8	operating income	us-gaap:OperatingIncomeLoss	-\$664.6M	2025-12-31	2026-02-12	10-K	0001193125-26-048957
9	book equity	us-gaap:StockholdersEquity	\$1.9B	2025-12-31	2026-02-12	10-K	0001193125-26-048957
10	liabilities	us-gaap:Liabilities	\$343.4M	2025-12-31	2026-02-12	10-K	0001193125-26-048957
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$3.5M	2025-12-31	2026-02-12	10-K	0001193125-26-048957
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$37.3M	2024-12-31	2026-02-12	10-K	0001193125-26-048957
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$371.2M	2023-12-31	2026-02-12	10-K	0001193125-26-048957
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.2M	2022-12-31	2025-02-11	10-K	0000950170-25-017899
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$914,000	2025-12-31	2026-02-12	10-K	0001193125-26-048957
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$142.8M	2024-12-31	2026-02-12	10-K	0001193125-26-048957
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.9M	2024-12-31	2026-02-12	10-K	0001193125-26-048957
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$260.4M	2023-12-31	2026-02-12	10-K	0001193125-26-048957
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$9.5M	2023-12-31	2026-02-12	10-K	0001193125-26-048957
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$495.7M	2022-12-31	2025-02-11	10-K	0000950170-25-017899
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$37.2M	2022-12-31	2025-02-11	10-K	0000950170-25-017899
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$19.5M	2025-12-31	2026-02-12	10-K	0001193125-26-048957
23	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	-\$578.0M	2025-12-31	2026-02-12	10-K	0001193125-26-048957
24	income tax	us-gaap:IncomeTaxExpenseBenefit	\$3.6M	2025-12-31	2026-02-12	10-K	0001193125-26-048957
25	current assets	us-gaap:AssetsCurrent	\$1.9B	2024-12-31	2026-02-12	10-K	0001193125-26-048957
26	current liabilities	us-gaap:LiabilitiesCurrent	\$87.8M	2024-12-31	2026-02-12	10-K	0001193125-26-048957
27	assets	us-gaap:Assets	\$2.2B	2023-12-31	2025-02-11	10-K	0000950170-25-017899
28	assets	us-gaap:Assets	\$2.2B	2022-12-31	2024-02-21	10-K	0000950170-24-017571
29	shares outstanding	dei:EntityCommonStockSharesOutstanding	95,985,312	2026-02-10	2026-02-12	10-K	0001193125-26-048957
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	85,774,474	2025-02-07	2025-02-11	10-K	0000950170-25-017899